UTime initiates financial and legal due diligence on Bowen Therapeutics

UTime has commenced a comprehensive financial and legal due diligence on Bowen Therapeutics, which it intends to acquire. Bowen Therapeutics is expected to become a key part of UTime’s expansion strategy. Bowen Therapeutics’ progress in the development of monkeypox vaccine has contributed a number of breakthrough technologies to global healthcare. UTime intends to leverage the proposed acquisition to integrate Bowen Therapeutics’s advanced technologies and research and development capabilities in order to facilitate the company’s technological innovation and market expansion in the healthcare sector.